PubHawk
Ann Neurol October 2009 PMID 19847908

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Kathleen Hawker, Paul O'Connor, Mark S Freedman, Peter A Calabresi, Jack Antel, Jack Simon, Stephen Hauser, Emmanuelle Waubant, Timothy Vollmer, Hillel Panitch, Jiameng Zhang, Peter Chin, Craig H Smith

Download social card

Mentions

28
Peak: 7 in Aug 2020
across 5 sources since Feb 2019

Extended reach

145,069
potential audience

Total likes

613

Video views

38,759

Mentions per month

Feb 2019 – Jun 2024

Where it's discussed

  • X / Twitter19 posts
  • News4 articles
  • YouTube2 videos
  • Blogs2 articles
  • Bluesky1 posts

AI synopsis

What people are saying

The discussions reflect a balanced perspective on the research, with posts referencing the study’s findings that rituximab reduced new brain lesions but did not significantly alter overall disease progression, and they include comparisons to other treatments like Ocrevus. The tone and context prioritize understanding the drug's specific effects and its role in shaping future treatment strategies.

AgreementModerate agreement

Most discussions acknowledge that rituximab shows promise in specific subgroups but recognize its limited overall efficacy in delaying disease progression compared to placebo.

InterestModerate interest

The posts demonstrate moderate interest, with users engaging in summaries of the study and comparisons with other treatments, though some posts show more interest in treatment history or broader options.

EngagementModerate engagement

Discussions include references to previous studies, subgroup analyses, and real-world implications, indicating a moderate level of detailed engagement.

ImpactModerate impact

Users highlight the potential of rituximab to affect disease markers like brain lesions, emphasizing its significance especially for younger patients, thus reflecting a perceived meaningful impact.

Abstract in brief

  • The study tested rituximab, a drug that targets B cells, in patients with primary progressive multiple sclerosis (PPMS) over 96 weeks, but it did not significantly delay disease progression compared to placebo.
  • Rituximab treatment resulted in a notable decrease in new T2 brain lesions, but there was no significant difference in overall brain volume loss between the two groups; certain subgroups like younger patients and those with active lesions showed delayed disease progression.
  • While adverse events were similar between groups, serious infections were more common in the rituximab group, and infusion reactions were more frequent during the first treatment, though they decreased with subsequent doses.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Aaron Boster MD
@AaronBosterMD · X

Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 28 likes · 5 shares · 13,102 followers View post →
Aaron Boster MD
@AaronBosterMD · X

Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 20, 2020 · 12 likes · 4 shares · 13,102 followers View post →
Dragana Obradovic
@DraganaObrado20 · X

@Nenad97320513 @Marija94325080 #Ocrelizumab je jedini registrovani lek za PPMS. Izvestan efekat je imao #rituximab kod mlađih sa aktivnom PPMS

Apr 14, 2020 · 7 likes · 1 share · 3,054 followers View post →
Dr. Brandon Beaber
@Brandon_Beaber · X

@Nat1401Natalie I have a video reviewing progressive MS treatment options: https://t.co/Ko7m9rmQE1 1:54​ Rituximab (rituxan/truxima) 3:16​ Ocrevus 5:41​ Tysabri 8:15​ Methotrexate 13:38​ Ibudilast 14:55​ simvastatin (zocor) 16:04​ HSCT (hematopoietic stem cell transplant) 17:29: Wahls Protocol

May 7, 2021 · 6 likes · 1 share · 18,195 followers View post →
Dr. Brandon Beaber
@Brandon_Beaber · X

@DrPHO_ID @GraceGombolayMD rituximab has been used widely in MS since the early 2000s and has two published randomized trials showing results similar to Ocrevus. HERMES: https://t.co/T9PnzcpdVc OLYMPUS: https://t.co/XhCQVnu48f

Sep 3, 2022 · 3 likes · 18,434 followers View post →
racHELL
@0xdaeda1a.bsky.social · Bluesky

For example pubmed.ncbi.nlm.nih.gov/19847908/ The keywords to look for are “CDP,” “confirmed disease progression,” and “volume” as in “brain volume loss.” As in Rituximab didn’t significantly affect either vs placebo.

Jun 6, 2024 · 3 likes View post →

All mentions

Dr. Brandon Beaber
@Brandon_Beaber · X

@word_working Here is a video on progressive MS treatments: https://t.co/62jPtOVOQE

Jun 10, 2024 · 1 like · 18,195 followers View post →
racHELL
@0xdaeda1a.bsky.social · Bluesky

For example pubmed.ncbi.nlm.nih.gov/19847908/ The keywords to look for are “CDP,” “confirmed disease progression,” and “volume” as in “brain volume loss.” As in Rituximab didn’t significantly affect either vs placebo.

Jun 6, 2024 · 3 likes View post →
Dr. Brandon Beaber
@Brandon_Beaber · X

@DrPHO_ID @GraceGombolayMD rituximab has been used widely in MS since the early 2000s and has two published randomized trials showing results similar to Ocrevus. HERMES: https://t.co/T9PnzcpdVc OLYMPUS: https://t.co/XhCQVnu48f

Sep 3, 2022 · 3 likes · 18,434 followers View post →
Dr. Brandon Beaber
@Brandon_Beaber · X

@Nat1401Natalie I have a video reviewing progressive MS treatment options: https://t.co/Ko7m9rmQE1 1:54​ Rituximab (rituxan/truxima) 3:16​ Ocrevus 5:41​ Tysabri 8:15​ Methotrexate 13:38​ Ibudilast 14:55​ simvastatin (zocor) 16:04​ HSCT (hematopoietic stem cell transplant) 17:29: Wahls Protocol

May 7, 2021 · 6 likes · 1 share · 18,195 followers View post →
Isatou Sarr
@IsatouSarr4 · X

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-con… https://t.co/9MfhQJgXba

Apr 27, 2021 · 1 like · 42 followers View post →
めんそ
@GOGOibudi · X

イブちゃんも... https://t.co/cVEusMKhmf

Aug 19, 2020 · 1 like · 76 followers View post →
@withMSartists
@withmsartists · X

RT @AaronBosterMD: Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 5 shares · 44 followers View post →
See @theMSguide
@DJS_KBO · X

RT @AaronBosterMD: Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 5 shares · 1,025 followers View post →
Enrique Gomez
@enriquegf11 · X

RT @AaronBosterMD: Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 5 shares · 327 followers View post →
MS awareness
@InlandMssa · X

RT @AaronBosterMD: Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 5 shares · 633 followers View post →
Aaron Boster MD
@AaronBosterMD · X

Progressive Multiple Sclerosis Treatments https://t.co/0vGFABVjqm via @Brandon_Beaber https://t.co/cZX0wQbW5T

Aug 19, 2020 · 28 likes · 5 shares · 13,102 followers View post →
م .ماجد السبيعي
@wxwx45 · X

RT @AaronBosterMD: Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 21, 2020 · 4 shares · 85 followers View post →
Luisa Matias
@luisamatias · X

RT @AaronBosterMD: Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 21, 2020 · 4 shares · 594 followers View post →
Dr. Brandon Beaber
@Brandon_Beaber · X

RT @AaronBosterMD: Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 20, 2020 · 4 shares · 18,195 followers View post →
Ian Knowles
@IanKnow80953422 · X

RT @AaronBosterMD: Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 20, 2020 · 4 shares · 772 followers View post →
Aaron Boster MD
@AaronBosterMD · X

Rituximab for Multiple Sclerosis, excellent video by Dr. Brandon Beaber .@Brandon_Beaber: https://t.co/ZWXGvLQFdg

May 20, 2020 · 12 likes · 4 shares · 13,102 followers View post →
Mirjana Micanovic
@MirjanaMicanov2 · X

RT @DraganaObrado20: @Nenad97320513 @Marija94325080 #Ocrelizumab je jedini registrovani lek za PPMS. Izvestan efekat je imao #rituximab kod…

Apr 14, 2020 · 1 share · 255 followers View post →
Dragana Obradovic
@DraganaObrado20 · X

@Nenad97320513 @Marija94325080 #Ocrelizumab je jedini registrovani lek za PPMS. Izvestan efekat je imao #rituximab kod mlađih sa aktivnom PPMS

Apr 14, 2020 · 7 likes · 1 share · 3,054 followers View post →
Medicina del Aprendizaje
@dumerpedraza · X

El rituximab podría retrasar la discapacidad en pacientes con esclerosis múltiple secundaria progresiva Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis https://t.co/qrRoUULWU2 https://t.co/LffGpQeMLJ

Feb 16, 2019 · 66 followers View post →
Resignificando
@Rector_ARP · X

El rituximab podría retrasar la discapacidad en pacientes con esclerosis múltiple secundaria progresiva Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis https://t.co/VVZjZWVP7p https://t.co/VVZjZWVP7p

Feb 16, 2019 · 19 followers View post →